Tadeusz Robak

Medical University of Lodz

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (11)

Martin Šimkovič

Fakultní Nemocnice Hradec Králové

CZECH REPUBLIC

Aleksander Radosław Rycerz

Medical University of Lodz

Pawel Robak

Medical University of Lodz

Magdalena Witkowska

Medical University of Lodz

Wojciech Biernat

Gdański Uniwersytet Medyczny

Hartmut Döhner

Jan Novak

CZECH REPUBLIC

Jaroslaw D Kasprzak

Medical University of Lodz

Pau Montesinos

Ewa Robak

Medical University of Lodz

Marcin Braun

Medical University of Lodz

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tadeusz Robak

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (11)

Martin Šimkovič

Aleksander Radosław Rycerz

Pawel Robak

Magdalena Witkowska

Wojciech Biernat

Hartmut Döhner

Jan Novak

Jaroslaw D Kasprzak

Pau Montesinos

Ewa Robak

Marcin Braun

Make your next move.

Tadeusz Robak

Research Interests

Explore related searches

Contact this professor

Articles (20)

Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview

Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update

Successful treatment with cladribine in a patient with Rosai–Dorfman disease complicated by severe, prolonged marrow aplasia

Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia

Atypical Chronic Lymphocytic Leukemia—The Current Status

The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies

Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials

Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment

Collaborators (11)

Martin Šimkovič

Aleksander Radosław Rycerz

Pawel Robak

Magdalena Witkowska

Wojciech Biernat

Hartmut Döhner

Jan Novak

Jaroslaw D Kasprzak

Pau Montesinos

Ewa Robak

Marcin Braun

Make your next move.